In 2012, the FDA approved Amyvid (florbetapir F 18), a radiopharmaceutical for use in PET imaging of the brain to determine the presence of beta-amyloid plaque indicating Alzheimer’s Disease in patients with signs of dementia. Because no effective treatment for Alzheimer’s was available, Amyvid was not approved by the Centers for Medicare and Medicaid Services (CMS) for coverage. However, with the recent FDA approval of Alzheimer’s treatment Aduhelm (aducanumab), Amyvid will be in demand for diagnostic imaging.
ARA has been offering the Amyvid PET/CT scan for several years and has participated in continued research on its efficacy. The molecular radiology team anticipates that Amyvid will be cleared for coverage by CMS in the near future and we are prepared to meet your imaging needs.
ARA continues to follow CDC guidelines in requiring employees and patients to wear masks at our imaging centers for the safety of all.